DAWN HALKUFF - 20 Nov 2023 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Director
Signature
/s/ Beth Hecht, as Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
20 Nov 2023
Net transactions value
+$9,954
Form type
4
Filing time
21 Nov 2023, 16:20:16 UTC
Previous filing
07 Jun 2023
Next filing
05 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Purchase $9,954 +5,410 $1.84 5,410 20 Nov 2023 By; DAWN HALKUFF REVOCABLE TRUST U/A DTD 08/25/2017 F1
holding XERS Common Stock 57,500 20 Nov 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.